Actinium Pharmaceuticals (ATNM) said Monday it signed a supply agreement with Eckert & Ziegler for Actinium-225.
Financial details weren't disclosed.
Under the agreement, Actinium Pharmaceuticals will access Eckert & Ziegler's high-quality Actinium-225 to advance Actimab-A and other development candidates for US and international clinical trials.
Ac-225 targeted radiotherapy offers precise cancer treatment by delivering high-energy alpha particles with minimal penetration. Actimab-A is an Ac-225-based therapy that specifically targets CD33, a receptor overexpressed in acute myeloid leukemia and other myeloid disorders, the company said.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。